A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

December 10, 2021

Study Completion Date

December 10, 2021

Conditions
Refractory Infantile Spasms
Interventions
DRUG

JBPOS0101

JBPOS0101 (investigational product)

Trial Locations (23)

19104

The Children's Hospital of Philadelphia (CHOP), Philadelphia

23298

Virginia Commonwealth University, Richmond

27710

Duke University Medical Center, Durham

30093

Center for Rare Neurological Diseases, Norcross

32789

Pediatric Neurology, PA, Winter Park

33155

Nicklaus Children's Hospital, Miami

40202

University of Louisville School of Medicine, Louisville

41404

Kyungpook National University Chilgok Hospital (KNUH), Daegu

44195

Cleveland Clinic, Cleveland

50612

Pusan National University Yangsan Hospital, Pusan

55905

Mayo Clinic, Rochester

72202

Arkansas Children's Hospital, Little Rock

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital LA, Los Angeles

90095

UCLA - David Geffen School of Medicine, Los Angeles

94143

UCSF Epilepsy Center, San Francisco

97239

Oregon Health and Science University, Portland

98405

Multicare Institute for Research and Innovation, Tacoma

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Bio-Pharm Solutions Co., Ltd.

INDUSTRY